Toronto Dominion Bank Buys 70,551 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Toronto Dominion Bank grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 710,523 shares of the biopharmaceutical company’s stock after acquiring an additional 70,551 shares during the period. Toronto Dominion Bank owned 0.06% of Gilead Sciences worth $65,631,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. HHM Wealth Advisors LLC grew its position in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences in the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences in the fourth quarter worth about $29,000. Crews Bank & Trust bought a new position in Gilead Sciences during the 4th quarter worth about $31,000. Finally, Stephens Consulting LLC increased its position in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at $19,977,938.37. This trade represents a 9.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have sold 25,429 shares of company stock valued at $2,894,445. 0.27% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on GILD shares. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 25th. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Bank of America increased their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, Royal Bank of Canada raised their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $102.50 on Friday. The company has a market cap of $127.50 billion, a P/E ratio of 277.03, a PEG ratio of 0.71 and a beta of 0.26. The firm has a fifty day moving average price of $105.75 and a 200 day moving average price of $99.76. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the previous year, the business earned ($1.32) EPS. Gilead Sciences’s revenue for the quarter was down .3% on a year-over-year basis. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 3.08%. Gilead Sciences’s dividend payout ratio is currently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.